Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: PRACTICAL ASPECTS AND DISCUSSION ISSUES OF RATIONAL PHARMACOTHERAPY

https://doi.org/10.20996/1819-6446-2017-13-6-856-862

Full Text:

Abstract

Atrial fibrillation (AF), being both a cause and a consequence of chronic heart failure (CHF), occurs with it significantly more often than in the general population. Prevention and treatment of AF in patients with CHF has its own specifics and presents certain difficulties for practical physicians of various specialties. The article presents a modern view of primary and secondary prevention of AF in patients with CHF and a critical analysis of international recommendations on the use of various antiarrhythmics and not antiarrhythmic drugs, anticoagulants and non-drug treatments in these patients. Based on the analysis of a number of studies, it has been shown that in patients with AF and CHF, the sinus rhythm control strategy has no advantages over the rate control strategy. The review also examines the possibilities of drug therapy in rate control strategy in CHF, depending on the size of the left ventricular ejection fraction, as well as indications for interventional prophylaxis of the AF paroxysms. At the same time, it discusses some questions about the choice of tactics for management of patients with AF and CHF, electrical and pharmacological cardioversion and prevention therapy, features of AF treatment in certain diseases and syndromes. The article also presents a critical evaluation of interventions in the treatment of AF, such as catheter ablation of AF, catheter ablation of additional routes and destruction of the AV node in combination with the pacemaker implantation.

About the Authors

Yu. А. Bunin
Russian Medical Academy of Continuous Professional Education
Russian Federation

Yuri A. Bunin – MD, PhD, Professor, Chair of Cardiology 

Barrikadnaya ul. 2/1, Moscow, 123995



S. V. Miklishanskaya
Russian Medical Academy of Continuous Professional Education
Russian Federation

Sofia V. Miklishanskaya – MD, PhD, Assistant, Chair of Cardiology 

Barrikadnaya ul. 2/1, Moscow, 123995



References

1. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442. doi: 10.1093/eurheartj/ehn309.

2. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol. 2003;93:2D-8D. doi: 10.1016/S0002-9149(02)03373-8.

3. Schneider M.P., Hua T.A., Bohm M. et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55:2299-307. doi: 10.1016/j.jacc.2010.01.043.

4. Healey J.S., Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9. doi: 10.1016/j.jacc.2004.11.070.

5. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration wit EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ehw210

6. Swedberg K., Zannad F., McMurray J.J. et al. Eplerinone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF study. J Am Coll Cardiol. 2012;59:1598-603. doi: 10.1016/j.jacc.2011.11.063.

7. Martin R.R., Pogoryelova O., Koref M.S. et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart. 2014;100:1506-10. doi: 10.1136/heartjnl2014-305482.

8. Mc Murray J.J., Packer M., Desai A.S. et al. Paradigm-HF investigators and committees. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.

9. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130:e199–e267. https://doi.org/10.1161/CIR.0000000000000041

10. Hess P.L., Jackson K.P., Hasselblad V. Al-Khatib S.M.. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A Systematic Review and Meta-Analysis. Curr Cardiol Rep. 2013;15(2):330. doi:10.1007/s11886-012-0330-6

11. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-200. doi: 10.1093/eurheartj/ehw128.

12. Roskell N.S., Samuel M., Noack H. et al. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013;15:787-97. doi: 10.1093/europace/eut001.

13. Update European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-51. doi: 10.1093/europace/euv309.

14. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY steering committee and investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi: 10.1056/NEJMoa0905561.

15. Patel M.R., Mahaffey K.W., Gard J. et al. ROCKET-AF investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi: 10.1056/NEJMoa1009638.

16. Granger C.B., Alexander J.H., Mc Murray J.J. et al. ARISTOTLE committees and investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi: 10.1056/NEJMoa1107039.

17. Holmes D.R., Doshi S.K., Kar S. et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65:261423. doi: 10.4330/wjc.v9.i2.139.

18. Bunin Yu.A., Miklishanskaya S.V. Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Ration Pharmacother Cardiol. 2016;12(4):465-70. (In Russ.) [Бунин Ю.А., Миклишанская С.В. Клиническое значение новых оральных антикоагулянтов в профилактике тромбоэмболических осложнений у больных с фибрилляцией предсердий: не все мечты сбываются. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):465-470]. doi: 10.20996/1819-6446-201612-4-465-470.

19. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;385:2667-77. doi: 10.1056/NEJMoa0708789.

20. Van Gelder I.C., Groenveld H.F., Crijns H.J. et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. doi: 10.1056/NEJMoa1001337.

21. Kotecha D., Holmes J., Krum H. et al. Beta-blockers in heart failure collaborative group. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data metaanalysis. Lancet. 2014;384:2235-43. doi: 10.1016/S0140-6736(14)61373-8.

22. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opion Cardiol. 2000;15:4153.

23. Bardy G.H., Lee K.L., Mark D.B. et al. Amiadarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. doi: 10.1056/NEJMoa043399


For citation:


Bunin Y.А., Miklishanskaya S.V. ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: PRACTICAL ASPECTS AND DISCUSSION ISSUES OF RATIONAL PHARMACOTHERAPY. Rational Pharmacotherapy in Cardiology. 2017;13(6):856-862. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-856-862

Views: 183


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)